SNB advises Boehringer Ingelheim on the acquisition of Labor Dr. Merk & Kollegen GmbH
With the transaction, which was completed on March 15, 2021, Boehringer Ingelheim has acquired the virology competence center Labor Dr. Merk & Kollegen GmbH in Ochsenhausen. Founded in 1971, the family-owned company is located in close to Boehringer Ingelheim's largest research and development site in Biberach, Germany, and has established a GMP virus production facility in recent years. With the acquisition, Boehringer Ingelheim strengthens its research & development and clinical manufacturing capabilities for ATMP (advanced therapy medicinal products) in the field of immuno-oncology.
Boehringer Ingelheim was supported for the first time by the Hamburg office of SNB (Dr. Mark-Alexander Huth, Nils Bräuninger, Johannes Thies) in the legal aspects of the transaction preparation and support as well as in the contract negotiations.